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Intracellular cyclic adenosine monophosphate
(cAMP) suppresses innate immunity by inhibiting
proinflammatory cytokine production from mono-
cytic cells. Enhanced expression of interleukin-10
(IL-10) has been suggested to be the mechanism of
suppression. However, cAMP is still capable of sup-
pressing production of the cytokines TNF-a and
IL-12 in IL-10-deficient dendritic cells (DCs). Here,
we demonstrated that the transcription factor c-Fos
was responsible for the cAMP-mediated suppression
of inflammatory cytokine production. c-Fos accumu-
lated at high amounts in response to cAMP and
lipopolysaccharide (LPS). Overexpression of c-Fos
suppressed LPS-induced cytokine production,
whereas cAMP-mediated suppression of TNF-a and
IL-12 was impaired in Fos/ DCs or in RAW264.7
cells treatedwith c-Fos siRNA. c-Fos physically inter-
actedwithp65protein and reduced the recruitment of
p65 to the Tnf promoter. Multiple sites of c-Fos
were phosphorylated by the IKKb protein. Thus, we
propose that c-Fos is a substrate of IKKb and is
responsible for the immunosuppressive effect of
cAMP.
INTRODUCTION
The Toll-like receptor (TLR) signaling pathway plays a central role
in innate immunity and is linked to the activation of adaptive
immunity. TLRs are activated by interaction with their cognate
ligands, such as lipopolysaccharide (LPS), followedby the activa-
tion of two distinct adaptor molecules, MyD88 and TRIF. The
MyD88and theTRIF signalingpathwaysactivate the transcription
factors, NF-kB and IRF3, leading to the transcriptional activation
of proinflammatory cytokines (TNF-a, IL-6, and IL-12) and inter-
ferons (IFNs) (Takeda and Akira, 2004). The TLR signal is strictly
regulated by anti-inflammatory cytokines, such as IL-10 (Takeda
et al., 1999), as well as various chemical and peptide mediators,
including prostaglandinE2 (PGE2) (Harris et al., 2002; Kabashima372 Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc.et al., 2002; Shiraishi et al., 2008), histamine (Jutel et al., 2002),
extracellular ATP (la Sala et al., 2001), vasoactive intestinal
peptide (VIP), and pituitary adenylate cyclase-activating peptide
(PACAP) in order to maintain homeostasis (Pozo, 2003). IL-10
has been shown to suppress proinflammatory cytokine produc-
tion through the transcription factor STAT3 (Takeda et al.,
1999), whereas other mediators act by elevating the concentra-
tion of intracellular cyclic adenosine monophosphate (cAMP).
cAMP has inhibitory effects on a variety of components of cell
activation, including phagocytosis (Aronoff et al., 2004), reactive
oxygen intermediate (ROI) generation (Dent et al., 1994), and the
production of inflammatory mediators such as TNF-a (Rowe
et al., 1997). The modulation of macrophage activation is impor-
tant for immunoregulation as well as resolution of inflammation,
yet the downstreammechanisms involved in these cAMP effects
remain to be elucidated.
Protein kinase A (PKA) was earlier thought to be the primary
effector of cAMP in eukaryotic cells (Walsh et al., 1968). In addi-
tion, exchange protein directly activated by cAMP (Epac) also
functions as a receptor for cAMP (de Rooij et al., 1998; Kawasaki
et al., 1998). Several reports suggested that PKA, rather than
Epac, is important for cAMP-mediated suppression of cytokine
production, whereas activation of Epac, but not PKA, dose
dependently suppresses phagocytosis (Aronoff et al., 2005).
However, the anti-inflammatory effect downstream of PKA or
Epac has not been discovered.
Antigen-presenting cells (APCs) treated with cAMP-elevating
reagents express reduced expression of costimulatory mole-
cules and enhanced amounts of IL-10 (Akasaki et al., 2004; Del-
gado et al., 2005), which induce Tr1-type regulatory T cells. The
upregulation of IL-10 by cAMP has been suggested to be an
important mechanism of suppression. However, our present
study demonstrated that cAMP was still capable of suppressing
TNF-a and IL-12 production in IL-10-deficient dendritic cells
(DCs). Therefore, an additional important mechanism other than
IL-10 is considered to exist. By using microarray analysis, we
identified c-Fos as a strong candidate for the mediator of cAMP
because it has been reported that deletion of the Fos gene
(encoding c-Fos) results in hyperinduction of proinflammatory
cytokines in response to LPS (Ray et al., 2006). However, the
mechanism of c-Fos-mediated suppression of proinflammatory
cytokine production has not been elucidated. We found that the
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c-Fos Accumulated by cAMP and IKKb Suppresses p65amounts of c-Fos protein induced by LPS+cAMP were much
higher than those induced by LPS or cAMP alone. cAMP mostly
upregulated c-Fos mRNA expression, whereas the kinase IKKb
activated by LPS directly phosphorylated c-Fos, leading to c-
Fos protein stabilization and accumulation. We identified one of
the critical residues of c-Fos for IKKb-mediated phosphorylation
and stabilization. These data indicate that c-Fos is a substrate of
IKKb and a therapeutic target for the suppression of endotoxin
shock and inflammatory diseases.
RESULTS
cAMP Suppresses TNF-a and IL-12 Production
Independently of IL-10
To investigate the molecular mechanism by which cAMP
suppresses proinflammatory cytokine production, we first
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Figure 1. Effect of 8-bromo-cAMP and
PGE2 on LPS-Induced Cytokine Production
in BMDCs
(A) BMDCs were stimulated with LPS (10 ng/ml),
cAMP, and PGE2 at the indicated concentrations
for 24 hr. The concentration of TNF-a, IL-6,
IL-10, and IL-12p70 in the culture supernatants
was measured by ELISA.
(B) BMDCs were stimulated with LPS in the pres-
ence or absence of cAMP (100 mM) for 3 hr, and
the mRNA was analyzed by RT-PCR (left panel)
and real-time PCR (right panel).
(C and D) BMDCs from (C) Il10+/- mice or Il10/
mice or those from (D) wild-type mice or Tie2-
Cre-Stat3fl/fl mice were stimulated with LPS and
cAMP for 24 hr. The concentrations of cytokines
were measured by ELISA.
All graphs are mean ± SD. n = 2. Representative of
three experiments.
confirmed that cAMP-activating reagents
(PGE2), as well as the membrane-perme-
able cAMP analog 8-bromo-cAMP
(simply referred to as cAMP hereafter in
this paper), equally suppressed TLR-
mediated proinflammatory cytokine
production. As reported previously (Kata-
kami et al., 1988; Kunkel et al., 1988),
PGE2 and cAMP strongly suppressed
LPS-induced TNF-a and IL-12p70
production from bone marrow-derived
dendritic cells (BMDCs) (Figure 1A) as
well as from RAW264.7 cells (data not
shown). IL-6 protein was decreased by
only half at the maximum amount of
cAMP or PGE2. cAMP suppressed the
mRNA expression of TNF-a, IL-12p40,
and IFN-b, but not those of IL-6 induced
by LPS in BMDCs (Figure 1B). In contrast,
the amount of anti-inflammatory cytokine
IL-10waselevated by LPS in the presence
of cAMP or PGE2 in BMDCs (Figures 1A
and 1B).
IL-10 is known to suppress the production of proinflammatory
cytokines through STAT3 (Takeda et al., 1999). Figures 1C and
1D show that cAMP still suppressed TNF-a and IL-12p70
production in BMDCs from IL-10- or STAT3-deficient mice.
These results indicate that a mechanism independent of the IL-
10-STAT3 pathway exists for the suppression of proinflamma-
tory cytokine production by cAMP.
cAMP Does Not Affect Intracellular TLR Signaling
Next, we examined the effect of cAMP on LPS signaling. LPS
induces the production of proinflammatory cytokines through
intracellular phosphorylation signaling cascades activated by
TLR4. As shown in Figure S1A available online, the phosphoryla-
tion and degradation of IkBa, as well as the phosphorylation of
MAP kinases, ERK, p38, and JNK, were not affected by cAMP.
Upon TLR signaling, the transcription factors NF-kB and IRF3
Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc. 373
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c-Fos Accumulated by cAMP and IKKb Suppresses p65were translocated into the nucleus and upregulated cytokine
mRNA transcription. The nuclear localization of the p65 subunit
of NF-kB and IRF3 was also unaffected by cAMP (Figure S1B).
These results indicate that the suppression by cAMP is not due
to the inhibition of the LPS-mediated intracellular signal trans-
duction pathways.
c-Fos Is a Candidate for the Mediator of the Inhibitory
Effect of cAMP
We next determined whether the suppression of cytokine mRNA
by cAMP requires de novo protein synthesis. In RAW264.7 cells,
the protein synthesis inhibitor cycloheximide (CHX) inhibited the
suppressive effect of cAMP on TNF-a and IFN-b mRNA (Fig-
ure 2A). Therefore, a protein induced by the LPS+cAMP signals
likely suppressed proinflammatory cytokine mRNA synthesis
induced by LPS. A microarray analysis was used to identify the
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Figure 2. c-Fos Protein Accumulation by
LPS+cAMP and c-Fos Overexpression
Suppresses TNF-a Production
(A) RAW264.7 cells were treated with cyclohexi-
mide (CHX; 20 mg/ml) and then stimulated with
LPS (10 ng/ml) and cAMP (100 mM) for 3 hr. The
mRNA expression was analyzed by RT-PCR and
real-time PCR. The gels show expression of the
indicated mRNA, and the graphs show quantita-
tion of TNF-a and IFN-b expression as a ratio of
G3PDH.
(B) Time course of the induction of c-Fos mRNA by
cAMP+LPS. RAW264.7 cells were stimulated with
LPS and cAMP for the indicated time. The c-Fos,
TNF-a, and IFN-b mRNA were analyzed by real-
time PCR.
(C) Induction of c-Fos mRNA by cAMP and LPS.
RAW264.7 cells were stimulated with cAMP and
LPS for 1 hr, and the c-Fos mRNA was analyzed
by RT-PCR and real-time PCR.
(D and E) Time course of the induction of c-Fos
protein by (D) LPS+cAMP or (E) LPS+PGE2.
RAW264.7 cells were stimulated with LPS,
cAMP, and PGE2 (10 nM) for the indicated time.
The c-Fos protein was analyzed by immunoblot.
(F) RAW264.7 cells were transfected with empty
EGFP or c-Fos-IRES-EGFP vectors. After 24 hr,
cells were stimulated with LPS in the presence of
Brefeldin A for 6 hr, followed by intracellular stain-
ing by the TNF-a antibody. TNF-a expression in
GFP-positive cells was analyzed by FACS (left
panel). GFP-positive cells were sorted by FACS
and then stimulated with LPS in the presence or
absence of cAMP for 3 hr. The mRNA of indicated
genes was analyzed by RT-PCR, and c-Fos
proteins were analyzed by immunoblot (right
panel).
All graphs are mean ± SD. n = 2. Representative of
three experiments.
genes induced by LPS+cAMP, but not
by LPS, stimulation. One of the genes
induced by LPS+cAMP, but not by LPS
alone, was inducible cAMP early
repressor (ICER), which has been shown
to be involved in the suppression of
TNF-a production by Calcitonin gene-related peptide (CGRP)
(Harzenetter et al., 2007). However, no suppression of LPS-
induced TNF-a production byCrem (encoding ICER) overexpres-
sion in RAW264.7 cells was observed in our system (data not
shown). Thus, we searched other targets and found that c-Fos,
a member of the AP-1 transcription factor, was upregulated by
cAMP+LPS. The c-Fos mRNA expression increased much
more strongly by LPS+cAMP than by LPS alone (Figure 2B).
We decided to analyze c-Fos further because c-Fos mRNA was
upregulated prior to the decrease of the TNF-a and IFN-
b mRNA expression by cAMP (Figure 2B). In addition, c-Fos
has been reported to negatively regulate LPS-mediated cytokine
production in macrophages (Ray et al., 2006).
cAMP signals seem to be important for the induction of c-Fos
mRNA because no additive effect was observed when cAMP
was given with LPS (Figure 2C). We also observed a marked
374 Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc.
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c-Fos Accumulated by cAMP and IKKb Suppresses p65increase of the c-Fos protein in response to LPS+cAMP
(Figure 2D) or LPS+PGE2 (Figure 2E). Although c-Fos mRNA
induction was transient and decreased after 1 hr stimulation
with LPS+cAMP (Figure 2B), the amount of c-Fos protein was
mainteined even after 6 hr treatment (Figures 2D and 2E). The
increase in c-Fos protein by LPS+cAMP was also observed in
BMDCs (data not shown). These data suggest that high accumu-
lation of c-Fos protein in response to cAMP+LPS might affect
LPS-induced inflammatory cytokine induction.
Forced Expression of c-Fos Inhibits TNF-a Production
To determine whether elevation of c-Fos protein was sufficient
for the suppression of proinflammatory cytokine production,
we measured TNF-a protein and mRNA expression in
RAW264.7 cells by intracellular immunostaining followed by
flow cytometry and RT-PCR analysis, respectively. RAW264.7
cells were transfected with Fos cDNA linked to the IRES-EGFP
or an empty vector carrying EGFP. After LPS stimulation, the
TNF-a expression was analyzed in GFP-positive cell fractions.
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Figure 3. c-Fos Is Required for cAMP-Medi-
ated Suppression of Cytokine Production
(A) The effect of Fos knockdown by RNAi. c-Fos
siRNA was transfected into RAW264.7 cells. After
24 hr, cells were stimulated with LPS (10 ng/ml)
and cAMP (100 mM) for 3 hr. The concentrations
of TNF-a were measured by ELISA (upper panel),
and c-Fos protein was analyzed by immunoblot
(lower panel).
(B) BMDCs from LysM-Cre-Fosfl/fl (indicated as
Fos/) and WT (Fos+/+) mice were stimulated
with LPS in the presence of Brefeldin A for 6 hr, fol-
lowed by intracellular staining by the TNF-a anti-
body.
(C) IL-12p40 mRNA expression in BMDCs from
LysM-Cre-Fosfl/fl (Fos/) mice were analyzed by
real-time PCR.
(D) The effect of c-Fos deficiency in DCs in vivo.
Fos+/+or Fos/mice spleen-derived DCs were
injected into OT-II mice. After 7 days, spleen and
lymph node cells were isolated and cultured with
PMA and ionomycin for 6 hr. The concentrations
of IFN-g were measured by ELISA.
All graphs are mean ± SD. n = 3. Representative of
two experiments.
As shown in Figure 2F (left panel), trans-
duction of Fos cDNA suppressed TNF-
a protein induction. This was confirmed
by RT-PCR. GFP-positive cells were
sorted, and then TNF-a mRNA expres-
sion was examined by RT-PCR. LPS-
induced TNF-a mRNA induction was
markedly inhibited by Fos transduction
(Figure 2F, right panel). Similarly, LPS-
induced IFN-b mRNA expression was
reduced by Fos overexpression (Fig-
ure 2F, right panel). c-Fos protein ex-
pressed by cDNA transfection after stim-
ulation with LPS alone was almost
comparable to c-Fos expression in cells
treated with cAMP+LPS (Figure 2F, right panel), suggesting that
the elevated c-Fos protein expression induced by cAMP+LPS
was high enough to suppress TNF-a production.
c-Fos Is Essential for cAMP-Dependent Suppression
of Inflammatory Cytokine Production
Next, to investigate whether c-Fos is necessary for cAMP-medi-
ated suppression of TNF-a production, we performed Fos RNAi
analysis in RAW264.7 cells. When c-Fos protein expression
was reduced by siRNA, cAMP-mediated suppression of TNF-
a production was hardly observed (Figure 3A). In addition, over-
expression of the dominant-negative c-Fos mutant A-Fos (Olive
et al., 1997) cancelled the suppressive effect of cAMP on LPS-
induced TNF-a and IFN-bmRNA upregulation (Figure S2). These
data indicate that c-Fos is necessary for the suppressive effect
of cAMP in RAW264.7 cells.
We further examined the physiological significance of c-Fos in
the cAMP-mediated suppression of inflammatory cytokine
production with Fos-disrupted cells. Dendritic cells (DCs) and
Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc. 375
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c-Fos Accumulated by cAMP and IKKb Suppresses p65macrophages from Fos-deficient micewere analyzed for LPS-in-
duced TNF-amRNA and protein expression (Figures 3B, 3C, and
S3). Suppression of TNF-a protein accumulation by cAMP was
weaker in Fos/ DCs than it was in Fos+/+ DCs (Figure 3B). In
fetal liver macrophages from Fos/mice, the suppressive effect
of cAMP on the TNF-amRNA expression was not as strong as it
was in Fos+/+ cells (Figure S3A). Similarly, the suppressive effect
of cAMP on IL-12p40 mRNA expression was severely impaired
in Fos/ DCs and fetal liver macrophages (Figures 3C and
S3A). These data indicate that c-Fos plays a critical role in the
cAMP-mediated suppression of proinflammatory cytokine
production.
To see the effect of Fos deficiency on DCs in vivo, we adop-
tively transferred Fos-deficient DCs into TCR-Tg (OT-II) mice
after antigen uptake. As shown in Figure 3D, the production of
IFN-g from Fos/ DC-transferred mice was higher than that of
Fos+/+ DC-transferred mice. These results suggest that c-Fos
functions as an anti-inflammatory mediator in vivo.
Recruitment of p65 to the Tnf Promoter Is Blocked
by c-Fos
The Tnf promoter was analyzed to elucidate the mechanism of
suppression by c-Fos. The 2.0 kb promoter region was cloned
and fused to the luciferase gene. LPS strongly upregulated this
Tnf promoter activity, which was suppressed by cAMP
(Figure 4A). Deletion analysis of the promoter region revealed
that 700 to 650 bp of the Tnf promoter containing the
NF-kB binding site (670 kB site) was important for LPS-
induced transcriptional activation as well as suppression by
cAMP. The ChIP assay confirmed that the p65 subunit of
NF-kB can interact with this region (700 to 490 bp) in
response to LPS and that the recruitment of p65 was blocked
by cAMP (Figure 4B, left, upper panels). In contrast, p65 recruit-
ment was not reduced but, rather, was enhanced by cAMP in the
Il6 promoter region (Figure 4B, left, lower panels). c-Fos and c-
Jun were also recruited to this region in a cAMP-independent
manner (Figure 4B, right panel).
To investigate whether c-Fos also blocks p65 recruitment to
the promoter, we transfected Traf6 and Fos cDNA into
RAW264.7 cells. TRAF6 is a mediator of TLR signaling, which
activates the IKK complex and NF-kB. Overexpression of Traf6
activated the Tnf promoter, but coexpression of Fos suppressed
the promoter activation (Figure 4C, left panel). Under these
conditions, Traf6 enhanced recruitment of p65 to the promoter,
whereas Fos overexpression suppressed this recruitment
(Figure 4C, right panel). These data suggest that both cAMP
and c-Fos suppress the induction of TNF-a mRNA by blocking
p65 recruitment to its promoter region.
To understand how c-Fos inhibits p65 recruitment to the
promoter region, we also performed DNA affinity precipitation
(DNAP) assays with the oligonucleotide of the Tnf promoter
region (670 kB site). In LPS-stimulated RAW264.7 cell nuclear
extracts, p65, but not p50, was bound to this oligonucleotide
(Figure 4D). Lack of binding of p50 to the 670 kB site was
confirmed in nuclear extracts from HEK293T cells overexpress-
ing p65 and p50 (Figure S4). These data suggest that the
670 kB site is preferentially recognized by the p65:p65 homo-
dimer, whereas the NF-kB consensus sequence is recognized
by the p50:p65 heterodimer, which is consistent with previous376 Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc.reports (Bohuslav et al., 1998; Chen et al., 1998). The amount of
p65 bound to the670 kB site oligonucleotide in the cell extracts
stimulated with LPS+cAMP was reduced compared with those
stimulated with LPS alone (Figure 4D). However, binding of p65
to the NF-kB consensus oligonucleotide was not inhibited by
cAMP (Figure 4D). Similar reduction of p65 binding to the
670 kB site oligonucleotide was observed when the nuclear
extracts were incubated with recombinant GST-c-Fos protein
(Figure 4E). As shown previously (Stein et al., 1993), p65 directly
bound to c-Fos (full-length 1–380 aa) (Figure 4F). The deletion
mutant c-Fos (111–380), but not c-Fos (1–220), interacted with
p65 (Figure 4F). c-Fos (111–380) as well as WT-c-Fos (1–380),
but not c-Fos(1–220), inhibited p65-mediated Tnf promoter lucif-
erase activation (Figure 4G, left panel). c-Fos (111–380), but not
c-Fos (1–220), blocked binding of p65 to the 670 kB site oligo-
nucleotide (data not shown). In contrast, Fos overexpression did
not affect p65-induced NF-kB consensus-promoter activation
(Figure 4G, right panel). Taken together, direct binding of c-Fos
to p65 seems to reduce affinity of p65 to the 670 kB site, but
not to the consensus kB site. A schematic model for the c-Fos-
mediated Tnf promoter suppression is shown in Figure S5.
cAMPUpregulates c-FosmRNA, whereas LPS Stabilizes
c-Fos Protein
We then investigated the molecular mechanism by which c-Fos
protein was drastically accumulated by LPS+cAMP. The c-Fos
protein has been reported to be very unstable and rapidly
degraded (Stancovski et al., 1995; Tsurumi et al., 1995). Phos-
phorylation by several kinases plays important roles in both the
degradation and stabilization of c-Fos protein (Chen et al., 1993;
Coronella-Wood et al., 2004; Murphy et al., 2002; Okazaki and
Sagata, 1995; Sasaki et al., 2006; Tanos et al., 2005). Therefore,
we tested the effect of inhibitors of protein kinases (Figures 5A
andS6A). Suppression of activationof the kinasebyeach inhibitor
was confirmed by immunoblot with an antibody specific to the
phosphorylated (activated) form of the kinases (data not shown).
Although thePKA inhibitorH89partially suppressedc-Fosprotein
accumulation, other inhibitors of GSK-3b, ERK, p38, and JNK did
not affect the c-Fos protein expression (Figure S6A).
Wortmannin, a PI3 kinase inhibitor, partly suppressed the
c-Fos protein accumulation and c-Fos mRNA induction
(Figure 5A). However, another PI3 kinase inhibitor, LY294002,
did not affect c-Fos protein and mRNA accumulation
(Figure 5A). Therefore, a wortmannin-sensitive protein kinase
that is different from PI3 kinase or downstream kinases may be
involved in the induction of c-Fos mRNA. Consistent with
c-Fos protein expression, LY294002 did not affect cAMP-
mediated suppression of TNF-a mRNA expression, whereas
wortmannin partially reversed the effect of cAMP (Figure S6B).
Interestingly, IKK-2 (IKKb) inhibitor (IKK2 inhibitor IV) almost
completely suppressed c-Fos protein accumulation but had little
effect on c-Fos mRNA induction (Figure 5A). Requirement of
IKKb was confirmed by the reduction of IKKb expression by
siRNA (Figure 5B). IKKb knockdown resulted in less c-Fos accu-
mulation by LPS+cAMP stimulation. These data suggest that
both LPS- and cAMP-induced signals are necessary for c-Fos
protein accumulation; however, cAMP signals are important for
c-Fos mRNA induction, whereas LPS-IKKb signals are more
important for c-Fos protein accumulation.
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Figure 4. The Effect of c-Fos on p65-Medi-
ated Tnf Promoter Activation
(A) RAW264.7 cells were transfected with the indi-
cated constructs of the Tnf promoter (2.0 kb,
0.7 kb, and0.65 kb) luciferase. After 24 hr, cells
were stimulated with LPS and cAMP for 3 hr and
then luciferase activity was measured. The puta-
tive NF-kB sites were predicted by TFSEARCH
(http://mbs.cbrc.jp/research/db/TFSEARCH.html),
and the sites with scores higher than 70 are shown.
Arrows indicate the positions of primers used for
the ChIP assay.
(B) ChIP assay. RAW264.7 cells were stimulated
with LPS and cAMP for 3 hr. DNA coprecipitated
with indicated antibodies was amplified by
PCR with primer sets for the Tnf promoter (700
to 490 bp) and Il6 promoter (307 to 72 bp)
regions (left panel). DNA coprecipitated with indi-
cated antibodies was analyzed by real-time PCR
with primer sets for the Tnf promoter (800 to
600 bp) region (right panel).
(C) RAW264.7 cells were transfected with Tnf
promoter (2.0 kb) luciferase, TRAF6, and c-Fos
expression vectors. After 24 hr, luciferase activities
were measured (left panel). RAW264.7 cells were
transfected with TRAF6 and c-Fos expression
vectors, and 24 hr later, the ChIP assay was per-
formed with primer sets for the Tnf promoter
(700 to 490 bp).
(D) Oligo-DNA precipitation (DNAP) assay.
RAW264.7 cells were stimulated with LPS and
cAMP for 3 hr. Nuclear extracts were incubated
with biotinylated oligonucleotides corresponding to
the STAT6-binding site (S6BS) (a negative control),
670 kB site of the Tnf promoter sequence (TNF-a),
or NF-kB consensus sequence (NF-kB). Proteins
precipitated with avidin beads were analyzed by
immunoblotting with indicated antibodies.
(E) DNAP assay with 670 kB site Tnf promoter.
Nuclear extracts of RAW264.7 cells stimulated with
LPS in the presence of the indicated amount of re-
combinant GST-c-Fos protein were incubated with
biotinylated oligonucleotides corresponding to the
670 kB site. The relative densities of oligonucleo-
tide-associated p65are indicated in the lower panel.
(F) Interaction between c-Fos and p65 in vitro.
RAW264.7 cells were stimulated with LPS for 1 hr.
The nuclear fraction was extracted and precipitated
with recombinant GST-c-Fos full-length (1–380 aa)
or deletion mutants (1–220 aa and 111–380 aa).
The precipitates were blotted with p65 antibody.
(G) The effect of c-Fos onTnfpromoter activity. RAW264.7 cells were transfectedwith the Tnf promoter (2.0 kb) luciferase (left) or NF-kBconsensus (3 3) (right) lucif-
erase together with p65 and c-Fos. After 24 hr, luciferase activity was measured.
All graphs are mean ± SD. n = 2. Representative of three (A–C) or two (D–G) experiments.IKKb Directly Phosphorylates and Stabilizes c-Fos
Protein
To investigate the molecular mechanism of the accumulation of
c-FosproteinbyLPS-IKKb signaling,weexamined thephosphor-
ylation of c-Fos protein in RAW264.7 cells. In several experi-
ments, c-Fos protein was detected as multiple bands on SDS-
PAGE with different molecular weights. This is probably due to
multiple phosphorylation because higher-molecular weight
species were not present with phosphatase (CIAP) treatment
(Figure 5C). We then examined the stability of c-Fos protein.c-Fos accumulated in response to pretreatment of RAW264.7
cells with cAMP+LPS, and then new protein synthesis was
blocked by adding cycloheximide (CHX). CHX treatment resulted
in a rapid disappearance of c-Fos protein; however, the upper
band stayed much longer than the lower band (Figure 5D).
Furthermore, both higher- and lower-molecular weight species
of c-Fos protein were accumulated in the presence of the protea-
some inhibitor MG132 in cAMP-treated RAW264.7 cells (Fig-
ureS7). Thesedata suggest that phosphorylation of c-Fosprotein
by LPS signals blocked proteasomal degradation of c-Fos.Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc. 377
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Figure 5. IKKb Phosphorylates and Stabi-
lizes c-Fos Proteins
(A) Effects of various kinase inhibitors on
LPS+cAMP-induced c-Fos protein. RAW264.7
cells were pretreated with the inhibitors
LY294002 (PI3K: 50 mM), wortmannin (PI3K:
100 nM), and IKK2 inhibitor IV (10 mM) for 30 min
and stimulated with LPS and cAMP for 3 hr. The
c-Fos protein and c-Fos mRNA were analyzed by
immunoblot and RT-PCR, respectively.
(B) The effect of IKKb knockdown on LPS+cAMP-
induced c-Fos protein. IKKb siRNA was trans-
fected into RAW264.7 cells. After 24 hr, cells
were stimulated with LPS (10 ng/ml) and cAMP
(100 mM) for 3 hr. The IKKb and c-Fos protein
were analyzed by immunoblot.
(C) RAW264.7 cells were stimulated with
LPS+cAMP, and cell extracts were immunopre-
cipitated by c-Fos antibody. Immunoprecipitates
were treated by CIAP and analyzed by immuno-
blot.
(D) RAW264.7 cells were stimulated with
LPS+cAMP for 2 hr and then treated with CHX
(10 mg/ml) for the indicated periods. c-Fos protein
was analyzed by immunoblot.
(E) FLAG-IKKb, IKKb KN (kinase-negative), IKKa,
IKKa KN, or p65 was coexpressed with HA-c-Fos
in HEK293T cells, and whole-cell extracts were
analyzed by immunoblot.
(F) FLAG-IKKb or IKKa were coexpressed with
HA-c-Fos in HEK293T cells, and cell extracts
were immunoprecipitated by HA antibody. Immu-
noprecipitates were treated by CIAP and analyzed
by immunoblot.
(G) HA-c-Fos was expressed alone or with FLAG-
IKKb or FLAG-IKKb KN in HEK293T cells, and
24 hr after transfection, cells were treated with
CHX (10 mg/ml) and 1 mM of actinomycin D
(ActD) for indicated periods. The protein and the
mRNA of HA-c-Fos were analyzed by immunoblot
and RT-PCR, respectively. Quantified relative
HA-c-Fos protein amounts are shown below.
Arrowheads indicate the lower-molecular weight
species of c-Fos protein. All graphs aremean ± SD.
n = 2. Representative of three experiments.To examine whether IKKb can directly induce phosphorylation
and accumulation of c-Fos protein, we analyzed the c-Fos
protein expression when IKKb was coexpressed in HEK293T
cells. As shown in Figure 5E, coexpression of IKKb, but not
a kinase-negative mutant of IKKb (IKKb KN), resulted in a drastic
increase in the c-Fos protein. In addition, IKKb expression
reduced the mobility of c-Fos protein on SDS-PAGE. This
reduced mobility of c-Fos was abolished by phosphatase treat-
ment (Figure 5F), indicating that IKKb phosphorylates c-Fos.
IKKa also induced a similar mobility shift of c-Fos protein;
however, generation of the lower-mobility species was much
weaker compared with IKKb (Figure 5E). An overexpression of
active forms of MEKK1, c-Raf and Akt, neither enhanced the
expression of c-Fos nor affected mobility on SDS-PAGE (data378 Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc.not shown). c-Fos protein expressed in HEK293T cells was
degraded rapidly; however, the coexpression of IKKb, but not
IKKb KN, prevented c-Fos protein from being degraded
(Figure 5G). These data suggest that the phosphorylation by
IKKb resulted in the stabilization of c-Fos protein.
Ser308 of c-Fos Is aMajor Phosphorylation Site for IKKb
Next, an in vitro kinase assay with GST-fused c-Fos proteins as
substrates was used to investigate direct phosphorylation of
c-Fos protein by IKKb. GST-c-Fos (full 1–380), but not GST,
was phosphorylated by IKKb, but not by IKKb-KN, as efficiently
as the control IkBa (Figure 6A). IKKa was also able to phosphor-
ylate GST-c-Fos, but the incorporation of 32P into the substrate
was much lower than it was by IKKb (data not shown). This is
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proteins by IKKa in HEK293T cells (Figure 5E). These data
suggest that c-Fos is a more suitable substrate for IKKb than
for IKKa.
To define the sites of phosphorylation by IKKb, we divided
c-Fos into several regions. Both the N-terminal (1–110 aa) and
C-terminal (221–380 aa) regions of c-Fos proteins were phos-
phorylated by IKKb in vitro (Figure 6A). Then, N- and C-terminal
regions were further divided into smaller regions with 30 to 60
amino acids. Multiple sites of c-Fos were apparently phosphor-
ylated by IKKb; however, region C2 (281–340) was most exten-
sively phosphorylated (Figure 6B). None of the serine-threonine
A B
C D
E
Figure 6. S308 of c-Fos Is a Major Site of
Phosphorylation by IKKb and Is Required
for Stabilization
(A–D) In vitro kinase assays were performed by
(A–C) FLAG-IKKb or FLAG-IKKb KN or by (D) LPS-
activated endogenous IKK complex by using
recombinant GST-c-Fos protein as a substrate.
Phosphorylated proteins and total GST proteins
were detected by autoradiography and CBB stain-
ing, respectively.
(E) c-Fos (WT), c-Fos (S308A), or c-Fos (S308D)
constructs fused to IRES-EGFP were transfected
into RAW264.7 cells, and 24 hr after transfection,
cells were stimulated by LPS for 3 hr.
The whole-cell extracts were analyzed by immu-
noblot. Arrowheads indicate the lower-molecular
weight species of c-Fos protein. Representative
of three experiments.
residues in this region have been recog-
nized as phosphorylation sites by ERKs,
RSK, or Mos (Chen et al., 1993; Murphy
et al., 2002; Okazaki and Sagata, 1995;
Sasaki et al., 2006). Thus, the C-terminal
region was further narrowed by a series
of deletions. This experiment determined
that region 301–317 contained major
phosphorylation residues in the C2 (218–
340) region (Figure 6C, left). This region
(301–317) contained only two serine resi-
dues, S308 and S310. We identified S308
as a major phosphorylation site by IKKb
in vitro (Figure 6C). To confirm the impor-
tance of this residue, we generated a full-
length c-Fos mutant carrying an S308A
substitution. GST-S308A c-Fos was very
weakly phosphorylated by the endoge-
nous IKK complex from LPS-stimulated
RAW264.7 cells compared to WT c-Fos
(Figure 6D). Thus, we concluded that
S308 is one of the major sites of phos-
phorylation by IKKb.
To investigate the role of S308 phos-
phorylation, we introduced S308A and
S308D mutations into the Fos cDNA.
S308D substitution may mimic the phos-
phorylation of c-Fos by IKKb. When tran-
siently expressed in RAW264.7 cells, the protein expression of
WT c-Fos was upregulated by LPS stimulation, whereas that
of c-Fos (S308A) was not upregulated by LPS (Figure 6E).
Importantly, the expression of the S308D mutant was already
high before LPS stimulation and was not further upregulated
by LPS (Figure 6E). Similar data were obtained when these
mutants were expressed in HEK293T cells together with
IKKb, although the expression of c-Fos (S308A) was still weakly
upregulated by IKKb (Figure S8). Nevertheless, these data
suggest that S308 is one of the, if not the only, important resi-
dues for stabilization of c-Fos induced by phosphorylation with
IKKb.Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc. 379
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Stimulation with prostaglandin E2 (PGE2), vasoactive intestinal
peptide (VIP), pituitary adenylate cyclase-activating peptide
(PACAP), histamine, and extracellular ATP has been reported to
have an immunosuppressive effect on various cell types,
includingmacrophages,DCs, andTcells. This suppressive effect
is explained by the elevation of intracellular cAMP through the
activation of adenyl cyclase (Di Virgilio et al., 2001; Harris et al.,
2002; Jutel et al., 2002; Pozo, 2003). However, the mechanism
for cAMP-mediated immune suppression has not been eluci-
dated. Here, we showed that the suppression works through
the upregulation of the c-Fos protein, which, in turn, prevents
the transcription of proinflammatory cytokines such as TNF-a.
We also demonstrated that IKKb-mediated phosphorylation
and stabilization of c-Fos are also keys for this mechanism.
Because c-Fos forms a family with FosB, Fra-1, and Fra-2, one
could argue whether other c-Fos family proteins could replace
c-Fos. We noticed that these related genes were not highly
induced in RAW264.7 cells (data not shown), which may explain
why siRNA for Fos almost completely abrogated the effect of
cAMP in RAW264.7 cells. However, Fos gene disruption did
not completely prevent the cAMP effect in fetal liver macro-
phages. This discrepancy could be due to compensation by
other Fos family proteins because other Fos family member
proteins (FosB, Fra-1, and Fra-2) were upregulated in Fos/
fetal-liver macrophages. Supporting this hypothesis, the overex-
pression of FosB or Fra-1 could suppress p65-induced Tnf
promoter activation. These data suggest that not only c-Fos
but also most other Fos family proteins are able to inhibit TNF-a
mRNA induction when they are highly expressed.
c-Fos is a component of AP-1, which is usually thought to be
involved in immune activation. For example, in T cells, AP-1 is
known to enhance IL-2 transcription in cooperation with NF-AT
(Jain et al., 1993). However, AP-1 is likely to be suppressive in
innate immunity. A suppressive role of AP-1 in TLR system has
been suggested in Drosophila (Kim et al., 2005). In mammals,
the suppression of proinflammatory cytokine production by AP-1
has been suggested not only by cAMP-elevating agents but also
by various stimuli, such as hepatocyte growth factor, macro-
phage-colonystimulating factor (M-CSF), andgranulocytemacro-
phage-colony stimulating factor (GM-CSF), which all upregulate
theERKpathway (Puig-Krogeretal., 2001).Because the transcrip-
tion of c-Fos is upregulated by the ERK pathway (Karin et al.,
1997), c-Fos may be widely involved in the suppression of proin-
flammatory cytokine production by the ERK-activating agents.
What is the relationship between cAMP and IL-10? Both inhibit
TNF-a and IL-12p40. We found that the effect of cAMP is inde-
pendent of the IL-10 and STAT3 pathway. IL-10 did not upregu-
late the c-Fos protein (data not shown). Conversely, cAMP
upregulated IL-10 production, suggesting that IL-10 partly
contributes to the cAMP-mediated suppression in normal condi-
tions. However, there are some differences between cAMP and
IL-10; cAMP suppresses IFN-b mRNA induction, but not that of
IL-6, whereas IL-10 suppresses IL-6 transcription, but not that of
IFN-b. The molecular mechanism of proinflammatory cytokine
suppression by the IL-10 and STAT3 pathway remained to be
elucidated. Interestingly, it has been reported that COX2 inhibitor
treatment of Il10/mice resulted in the rapid development of380 Immunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc.more severe colitis compared with untreated Il10/ mice
(Berg et al., 2002), suggesting that endogenous prostaglandins
are important inhibitors of the development of intestinal inflam-
mation in Il10/ mice. Therefore, the PGE2-cAMP system and
the IL-10 system are independent safeguards for preventing
excessive inflammation. These two pathways may also cooper-
atively suppress inflammation.
p50 often forms a heterodimer with p65 and regulates various
NF-kB-mediated gene expression. However, it has been shown
that p50 inhibits TNF-a production and that induction of p50 is
a mechanism of LPS tolerance (Bohuslav et al., 1998). Induction
of p50 may be a mechanism of the suppression by cAMP.
However, p50 expression did not differ between LPS and
LPS+cAMP. Thus, suppression of p65 activity on the Tnf
promoter by c-Fos is not by induction of p50.
The results of our study were consistent with the previous
report by Stein et al. (1993) showing that c-Fos protein directly
interacts with the p65.We further demonstrated that this interac-
tion reduced recruitment of p65 to the Tnf promoter region,
which can account for the suppressive effect of cAMP. Binding
of p65 to the670 kB site of the Tnf promoter region was appar-
ently reduced by the presence of c-Fos. This 670 kB site
(GTGAATTCCC) is highly conserved between humans and
rodents. The first half of this putative NF-kB binding site is
different than the consensus NF-kB (p50:p65 heterodimer)
recognition sequence (GGGRNTTTCC) and is probably prefer-
entially recognized by p65:p65 homodimer (Chen et al., 1998).
We confirmed the lack of p50 binding to this site by DNAP assay.
A possible role of p65:p65 homodimer in LPS-induced Tnf
promoter activation has been reported (Kuprash et al., 1995).
From those observations, we propose that p65:p65 homodimer
recognizes this critical GTGAATTCCC site, and the binding to
this sequence is blocked by the binding of c-Fos or AP-1
complex to p65:p65 homodimer. Although c-Fos did not affect
binding and transcriptional activity of p65:p50 heterodimer for
the consensus kB sequence, we still do not know why binding
of c-Fos to p65:p65 homodimer, but not p65:p50 heterodimer,
reduced the binding affinity to DNA. However, we think that
this model is quite attractive because it can explain how c-Fos
selectively affects NF-kB-dependent promoter activation.
Our results also demonstrate that c-Fos protein accumulation
is mediated by both LPS and cAMP signaling. Induction of
c-Fos mRNAwasmainly induced by a cAMP-wortmannin-sensi-
tive kinase pathway, and stabilization and accumulation of c-Fos
protein were mediated by the LPS-IKKb pathway, which directly
phosphorylated both the N- and C-terminal regions of c-Fos
proteins. The c-Fos protein is very unstable, though it is stabilized
by phosphorylation (Chen et al., 1993; Coronella-Wood et al.,
2004; Murphy et al., 2002; Okazaki and Sagata, 1995; Sasaki
et al., 2006; Tanos et al., 2005; Terasawa et al., 2003). These
reports have shown that serine-threonine kinases, such as
ERK, RSK, and Mos, stabilize c-Fos by phosphorylating S32,
T325, T331, S362, andS374.We generated deletions and substi-
tutionmutants for theseSer-Thr residues.However, noneof them
affected phosphorylation by IKKb in vitro and stabilization by
IKKb in HEK293T cells (data not shown). The current study iden-
tified a phosphorylation site, S308 of c-Fos by IKKb. To our
knowledge, this phosphorylation site has not been reported
previously and differs from the consensus amino acid sequence
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(Scheidereit, 2006). Although c-Fos (S308D) was more stable
than WT c-Fos before LPS stimulation or without coexpression
of IKKb, c-Fos (S308A) was still stabilized by IKKb. Because
IKKb also phosphorylates the N-terminal region of c-Fos, other
phosphorylation sites seem to be involved in full stabilization of
c-Fosprotein. Therefore, further study is necessary to completely
understand the mechanisms of c-Fos stabilization by IKKb
or LPS.
In conclusion, we propose that c-Fos and its family proteins
play important regulatory roles in innate immune systems. The
induction of c-Fos proteins could be therapeutic for preventing
acute and chronic inflammatory diseases, such as septic shock
or autoimmune diseases.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Reagents
Bone marrow-derived dendritic cells (BMDCs) were prepared from mouse
bone marrow cells as described (Hanada et al., 2005). RAW 264.7 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) contain-
ing 10% fetal bovine serum, antibiotics (GIBCO), and nonessential amino acids
(GIBCO). LPS (Escherichia coli serotype 055:B5) and 8-Bromoadenosine 3, 50-
cyclic monophosphate sodium salt (8-Br-cAMP) (B7880) were purchased from
Sigma. Prostaglandin E2 (PGE2), cycloheximide, and Actinomycin D were
purchased from Nacalai Tesque. Anti-c-Fos (sc-52), anti-p65 (sc-372), anti-
p50 (sc-1192), anti-c-Jun (sc-1694), anti-IKKg (sc-8330), anti-HA polyclonal
(sc-805), anti-GST (sc-138), and anti-GFP (sc-8334) antibodies were
purchased from Santa Cruz Biotechnology. Anti-Actin antibody (A2066) and
anti-FLAG M2 antibody (F3165) were purchased from Sigma. Anti-HA
(16B12) monoclonal antibody (MMS-101P) was purchased from Covance.
Anti-IKKb antibody (2678) was purchased from Cell Signaling Technology.
LY294002,wortmannin, and IKK-2 inhibitor IVwere obtained fromCalbiochem.
Calf intestinal alkaline phosphatase (CIAP) was obtained from TOYOBO.
Plasmids
Murine p65, murine Traf6, and human Fos cDNAs were amplified by RT-PCR.
The cDNAs were inserted into a pCMV vector (Takaesu et al., 2000), pCMV2-
FLAG vector (Sigma), or pcDNA3.1 vector (Invitrogen) to generate pCMV/
FLAG-p65, pCMV2/FLAG-TRAF6 and pCMV/FLAG-c-Fos, and pcDNA3.1/
HA(x2)-c-Fos, respectively. The various lengths of c-Fos deletion fragments
were amplified by PCR to generate pGEX5x-1/c-Fos deletion variants. The
point-mutated c-Fos mutants were generated by primers as follows: S308A,
50-CCTCTGCACgctGGCTCCCTGGGGATG-30 and 50-CATCCCCAGGGAGC
CagcGTGCAGAGG-30; S310A, 50-CACAGTGGCgccCTGGGGATG-30 and 50-
CATCCCCAGggcGCCACTGTG-30, S308/S310A; 50-CCTCTGCACgctGGC
gccCTGGGGATG-30 and 50-CATCCCCAGggcGCCagcGTGCAGAGG-30;
S308D, 50-CCTCTGCACgatGGCTCCCTGGGGATG-30 and 50-CATCCCCAGG
GAGCCatcGTGCAGAGG-30.
The FLAG-c-Fos WT, S308A or S308D fragment from pCMV/FLAG-c-Fos,
and the IRES-EGFP fragment from the pGCDDNsamI/E vector (Nishinakamura
et al., 2007) were inserted into the pcDNA3.1 vector (Invitrogen) to generate
pcDNA3.1/FLAG-c-Fos (WT, S308A or S308D)-IRES-EGFP. The GST-IkBa
(1–72) was kindly provided by Dr. T. Ishitani (Kyushu University). The murine
Tnf promoter 2.0 kb region was amplified by RT-PCR with the following
primers: forward, 50-GCGCGCTAGCGCTCCCCCAGGGCCATT-30 (2.0 kb),
50-GCGCGCAGCCAGAGTGAAAGGAGAAGGCT-30 (0.7 kb), and 50-GCGC
GCTAGCTCATTCCCTCTGGGGCTGCC-30 (0.65 kb); and reverse, 50-
GCGCAAGCTTGGTGTCTTTTCTGGAGGGAG-30. The amplified DNA frag-
ments were inserted into the Pickagene basic vector (TOYO Ink) to generate
the Tnf promoter-luciferase vector.
Mice and Primary Cells
Il10/ mice, Stat3fl/fl, and LysM-Cre/Fosfl/fl mice were obtained from
Dr. K. Takeda (Osaka University). The Fos/mice have been described previ-ously (Wang et al., 1992). Dendritic cells from bone marrow were generated as
described (Hanada et al., 2005). The macrophages derived from fetal liver
obtained by a modified method have also been described previously (Mason
et al., 2004). All experiments with thesemice were approved by and performed
according to the guidelines of the Animal Ethics Committee of Kyushu Univer-
sity, Fukuoka, Japan.
ELISA and RT-PCR
ELISA was performed with an ELISA kit (eBioscience). The total RNA of cells
was prepared with the RNAiso reagent (TAKARA), and RT-PCR was carried
out with the one-step RT-PCR kit (Applied Biosystems). Real-time PCR was
carried out with SYBR-Green (Applied Biosystems). The following oligonucle-
otides were used: G3PDH, 50-ACCACAGTCCATGCCATCAC-30 and 50-TCCA
CCACCCTGTTGCTGTA-30; TNF-a, 50-TGAACTTCGGGGTGATCGGTC-30 and
50-AGCCTTGTCCCTTGAAGAGGAC-30; IL-6, 50-GACTTCACAGAGGATAC
CAC-30 and 50-TCTCTCTGAAGGACTCTGGC-30; IL-12p40, 50-GTAGAGGT
GGACTGGACTCC-30 and 50-GCAGACAGAGACGCCATTCC-30; IL-10, 50-GG
ACAACATACTGCTAACCG-30 and 50-TTCATGGCCTTGTAGACACC-30; IFN-
b, 50-TCCAAGAAAGGACGAACATTCG-30 and 50-TGAGGACATCTCCCACG
TCAA-30; c-Fos, 50-CTGTCCGTCTCTAGTGCCAACTT-30 and 50-ATCTGTC
TCCGCTTGGAGCGTAT-30; and HA-c-Fos, 50-CCTACGATGTGCCCGATT
AT-30 and 50-TGGCTGCAGCCATCTTATTC-30.
Microarray Analysis
Microarray analysis was performed as described (Hanada et al., 2005). In brief,
BMDCs were unstimulated or stimulated with LPS (10 ng/ml) alone or with
LPS+cAMP (100 mM). The total RNA of BMDCs was isolated with Trizol (Invi-
trogen), and biotinylated cRNAs were synthesized with a one-cycle target-
labeling kit (Affymetrix). Fragmented cRNAs were hybridized to the Mouse
430 2.0 GeneChip (Affymetrix) and analyzed by GeneSpring.
Intracellular Staining
RAW264.7 cells were transfected with pcDNA3.1/FLAG-c-Fos-IRES-EGFP or
an empty EGFP vector. At 24 hr later, cells were stimulated with 10 ng/ml of
LPS and Brefeldin A for 6 hr. Cells were collected and fixed with an intracellular
staining kit (eBioscience) and stained with the anti-TNF-a-PE antibody and
analyzed by FACScalibur as previously described (Nishinakamura et al., 2007).
Reporter Gene Analysis
RAW264.7 cells were seeded onto 6-well plates 1 day before transfection as
described (Nishinakamura et al., 2007). The Tnf promoter luciferase vector
was cotransfected with cDNAs together with the b-galactosidase control
plasmid with FuGENE HD (Roche). The luciferase activities were measured
with the luciferase assay system (Promega) and normalized by internal control
b-gal activity.
RNAi Analysis
siRNA (50 nM) was transfected by Lipofectamine RNAi MAX (Invitrogen) into
RAW264.7 cells. The following siRNAs (sense strands) were used for RNAi
analysis for c-Fos and IKKb: c-Fos, GCAGATCTGTCCGTCTCTA; IKKb, GGA
CATCGTTGTTAGTGAA.
Adoptive Transfer of DCs
DCs from spleen cells were untreated or stimulated with OVA peptide (10 mg/
ml) and LPS (10 ng/ml). 1 3 106 cells were injected intravenously into OT-II
mice. After 7 days, lymph node cells were isolated, and 1 3 105 cells were
seeded into 96-well plates. Cells were stimulated with PMA and ionomycin
for 6 hr, and the concentrations of IFN-g were measured by ELISA.
ChIP Assay
The chromatin immunoprecipitation (ChIP) assay was performed as previously
described (Kinjyo et al., 2006) with a ChIP assay kit (Upstate Biotechnology).
Briefly, RAW264.7 cells were fixed with 1% formaldehyde at 37C for 5 min
and then suspended in an SDS lysis buffer. After sonication with 30 s pulses
10 times with a sonicator (Bioruptor; Cosmo Bio.), samples were incubated
with 5 mg antibodies or control IgG overnight at 4C. After the addition of
salmon sperm DNA and ProteinA-Agarose Slurry, the immunoprecipitates
were sequentially washed once with a low-salt buffer, a high-salt buffer, andImmunity 30, 372–383, March 20, 2009 ª2009 Elsevier Inc. 381
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eluted by heating at 65C for 6 hr. Proteins were then digested by proteinase
K, and RNAwas removed by the addition of 10 mg of RNase A. DNAwas recov-
ered by phenol/chloroform extraction and ethanol precipitation and then
subjected to PCR analysis. The following oligonucleotides were used to
amplify the mouse Tnf and mouse Il6 promoter regions: Tnf (700 to490 bp),
50-GCCACTTCCTCCAAGAACT-30 and 50-TTGGAAAGTTGGGGACACC-30;
Tnf (800 to 600 bp), 50-CTGTGGGACCTAAATGTCTG-30 and 50-GGGTAAT
GGGATGAGTATGG-30; and Il6 (307 to 72 bp), 50-TGCTCAAGTGCTGAG
TCACT-30 and 50-AGACTCATGGGAAAATCCCA-30.
DNA Affinity Purification Assay
The DNA affinity precipitation assay (DNAP) was performed as described
(Suzuki et al., 1993). Briefly, 50 mg nuclear extracts were incubated with
biotin-labeled oligonucleotides (0.5 mg) and poly dI-dC (5 mg) for 30 min in
a DNAP buffer. Then, Streptavidin-Dynabeads M-280 were mixed and rotated
for 1 hr at 4C. The precipitated proteins were analyzed by SDS-PAGE. The
following biotin-labeled oligonucleotides were used: NF-kB consensus,
50-GGATCAGGGACTTTCCGCTGGGGACTTTCCG-30; Tnf promoter (670 to
643 bp), 50-GTACGTGAATTCCCAGGGCTGAGTTCATTC-30; STAT6-binding
site, 50-GATCGCTTTTTTCCTCTAAACTGC-30.
In Vitro Kinase Assay
The IKK in vitro kinase assay was performed according to the procedure
described previously (Takaesu et al., 2001). IKKb was expressed in
HEK293T cells transfected with FLAG-IKKb or FLAG-IKKb KN and was immu-
noprecipitated by anti-FLAG (M2) antibody. IKK complex was also prepared
from RAW264.7 cells that were stimulated with LPS (100 ng/ml) for 1 hr by
immunoprecipitation with anti-IKKg antibody. GST proteins were purified by
glutathione Sepharose. Immunoprecipitates and 1 mg of GST proteins were
incubated with 5 mCi of [g-32P]-ATP at 30C for 5 min in kinase buffer
(10 mM HEPES-KOH [pH 7.4], 5 mM MgCl2, and 1 mM DTT). The phosphor-
ylated proteins were detected by SDS-PAGE followed by CBB staining and
autoradiography.
SUPPLEMENTAL DATA
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